Jin Medical International Ltd.
ZJYL · NASDAQ
9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 6.13 | -59.00 | 0.19 | 0.52 |
| FCF Yield | -0.55% | 1.76% | 2.87% | 5.45% |
| EV / EBITDA | 106.50 | 53.99 | 15.77 | 31.78 |
| Quality | ||||
| ROIC | 7.41% | 9.12% | 13.80% | 17.14% |
| Gross Margin | 40.43% | 34.23% | 32.30% | 30.64% |
| Cash Conversion Ratio | -0.35 | 1.08 | 0.58 | 2.22 |
| Growth | ||||
| Revenue 3-Year CAGR | 6.99% | -1.54% | 5.82% | 0.65% |
| Free Cash Flow Growth | -177.91% | 94.25% | -73.44% | 145.69% |
| Safety | ||||
| Net Debt / EBITDA | 0.87 | -0.91 | -1.55 | -1.14 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 277.23 |
| Efficiency | ||||
| Inventory Turnover | 1.97 | 2.23 | 1.89 | 2.05 |
| Cash Conversion Cycle | 243.33 | 225.57 | 158.62 | 147.95 |